VX661
CAS No. 1152311-62-0
VX661( Tezacaftor )
Catalog No. M10537 CAS No. 1152311-62-0
VX-661 is a second F508del CFTR corrector and is believed to help CFTR protein reach the cell surface. Phase 2.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 43 | In Stock |
|
| 5MG | 68 | In Stock |
|
| 10MG | 113 | In Stock |
|
| 25MG | 201 | In Stock |
|
| 50MG | 324 | In Stock |
|
| 100MG | 478 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameVX661
-
NoteResearch use only, not for human use.
-
Brief DescriptionVX-661 is a second F508del CFTR corrector and is believed to help CFTR protein reach the cell surface. Phase 2.
-
DescriptionVX-661 is a second F508del CFTR corrector and is believed to help CFTR protein reach the cell surface. Phase 2.
-
In Vitro——
-
In Vivo——
-
SynonymsTezacaftor
-
PathwayApoptosis
-
TargetCFTR
-
RecptorVFTR
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1152311-62-0
-
Formula Weight520.5
-
Molecular FormulaC26H27F3N2O6
-
Purity>98% (HPLC)
-
SolubilityDMSO: 100 mg/mL (192.12 mM)
-
SMILESO=C(C1(C2=CC=C(OC(F)(F)O3)C3=C2)CC1)NC4=CC5=C(N(C[C@@H](O)CO)C(C(C)(C)CO)=C5)C=C4F
-
Chemical Name(R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Pettit RS, Fellner C. P T. 2014 Jul;39(7):500-12. Veit G, et al. Sci Transl Med. 2014 Jul 23;6(246):246ra97.
molnova catalog
related products
-
CFTR corrector 4
CFTR corrector 4 is a potent and orally available transmembrane conductance regulator (CFTR) for cystic fibrosis and is a potent (R,R) type active enantiomer.
-
FDL169
FDL-169 is a novel and potent CFTR (Cystic fibrosis transmembrane conductance regulator) corrector for treating cystic fibrosis (CF) patients who carry the F508del mutation.
-
Nesolicaftor
PTI-428 specifically enhances cystic fibrosis transmembrane conductance regulator protein synthesis.
Cart
sales@molnova.com